<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403648</url>
  </required_header>
  <id_info>
    <org_study_id>6-101</org_study_id>
    <nct_id>NCT02403648</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Glucagon for Injection (Eli Lilly) and GlucaGenÂ® (Novo Nordisk) Administered by Subcutaneous and Intramuscular Injection in Normal, Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biodel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biodel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIOD-961 is a dry powder formulation of glucagon intended for use in a device that mixes
      (reconstitutes) the powder with liquid to make it easier for users to treat patients with
      severe hypoglycemia. The purpose of this study is to evaluate how much BIOD-961 absorbs into
      the bloodstream, how much it raises glucose concentrations (the intended effect) and compare
      to two glucagon products already on the market.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects receive on separate days, in random order one of the following: 1 mg BIOD-961
      intramuscularly (IM), 1 mg Lilly (IM), 1 mg Novo (IM), 1 mg BIOD-961 subcutaneously (SC), 1
      mg Lilly (SC), and 1 mg Novo (SC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon maximal concentration and area under curve</measure>
    <time_frame>240 minutes post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose maximal concentration and area under curve</measure>
    <time_frame>240 minutes after dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximal glucagon concentration</measure>
    <time_frame>240 minutes after dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximal glucose concentration</measure>
    <time_frame>240 minutes after dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal glucose excursion</measure>
    <time_frame>240 minutes after dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the glucose time curve from 0 to return to baseline after blood glucose peaked</measure>
    <time_frame>240 minutes after dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>BIOD-961, 1 mg IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular delivery of BIOD-961.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lilly Glucagon, 1 mg IM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular delivery of Lilly glucagon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novo Glucagon, 1 mg IM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular delivery of Novo glucagon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIOD-961, 1 mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous delivery of BIOD-961,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lilly Glucagon, 1 mg SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous delivery of Lilly glucagon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novo Glucagon, 1 mg SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous delivery of Novo glucagon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIOD-961</intervention_name>
    <description>BIOD-961 is a lyophilized glucagon formulation.</description>
    <arm_group_label>BIOD-961, 1 mg IM</arm_group_label>
    <arm_group_label>BIOD-961, 1 mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lilly Glucagon</intervention_name>
    <arm_group_label>Lilly Glucagon, 1 mg IM</arm_group_label>
    <arm_group_label>Lilly Glucagon, 1 mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novo Glucagon</intervention_name>
    <arm_group_label>Novo Glucagon, 1 mg IM</arm_group_label>
    <arm_group_label>Novo Glucagon, 1 mg SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index: 18.5-25.0 kg/m2 inclusive.

          -  Subject has provided informed consent and has signed and dated an informed consent
             form before any trial-related activities.

        Exclusion Criteria:

          -  Type 1 or type 2 diabetes mellitus.

          -  History of pheochromocytoma, insulinoma, glucagonoma, or glycogen storage disease.

          -  History of regular alcohol consumption as defined by alcohol intake exceeding 7 drinks
             per week for females or 14 drinks per week for males, where 1 drink = 5 ounces of wine
             or 12 ounces of beer or 1.5 ounces of hard liquor.

          -  Significant cardiovascular (to include New York Heart Association (NYHA) Class III or-
             IV functional capacity or uncontrolled hypertension), respiratory, gastrointestinal,
             hepatic, renal, neurological, psychiatric and/or hematological disease.

          -  Any significant cardiovascular event history, including angina, myocardial infarction,
             therapeutic coronary procedure (e.g, percutaneous transluminal coronary angioplasty,
             coronary bypass surgery), stroke, or transient ischemic attack.

          -  Females who are breast feeding, pregnant, or intending to become pregnant during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Morrow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institute for Clinical Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Krasner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Biodel</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>January 14, 2016</last_update_submitted>
  <last_update_submitted_qc>January 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

